Even if they lost $1 trillion in sales, large brand drug makers would still be the most profitable companies and would maintain current research investments, according to an analysis of publicly reported financial data by researchers at West Health Policy Center and Johns Hopkins Bloomberg School of Public Health . Conversely, the Congressional Budget Office last month estimated House drug pricing legislation, which has an industry impact of up to $1 trillion over six years, could lead to eight to...